Join to View Full Profile
1245 Wilshire BlvdSuite 303Los Angeles, CA 90017
Phone+1 213-977-1214
Fax+1 213-482-8868
Dr. Seneviratne is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2000 - 2001- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1999 - 2000
- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 1998 - 1999
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1995 - 1998
University of Colombo Faculty of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1996 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
- Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsClinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang
The Oncologist. 2024-06-03 - 2 citationsImproving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.Lee Schwartzberg, Davey Daniel, Daniel Vaena, Dennis Slater, Harry Staszewski
Future Oncology. 2023-06-01 - 33 citationsRandomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider
Journal of Thoracic Oncology. 2021-02-01
Press Mentions
Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early CancersMay 26th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
